Plain-English translation of NCT06629779 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called mevrometostat combined with , a standard prostate cancer treatment. Half of the participants will receive the new medication plus , and the other half will receive a placebo (a pill with no active ingredient) plus . Researchers want to see if adding this treatment helps slow or stop advanced prostate cancer that has stopped responding to hormone therapy.
Advanced prostate cancer that no longer responds to hormone therapy is difficult to treat, and patients need new options. This medication is designed to work in a different way than current treatments, and researchers believe it may help when combined with existing therapy.
You likely qualify if…
You likely don't qualify if…
You will visit the study clinic for screening to confirm you qualify. If enrolled, you will be randomly assigned to receive either the new medication (twice daily) plus the standard drug (once daily), or a placebo plus the standard drug. You will take these medications at home and attend regular clinic visits to check on your health, get blood tests, and monitor how well the treatment is working. The study includes a screening phase, treatment phase, safety follow-up, and long-term follow-up to track your health over time.
AI-generated summary from trial data · Sep 11, 2026 · Not medical advice
United States